145results about How to "Induced differentiation" patented technology

This invention provides methods of obtaining vaccines by use of non-stochastic methods of directed evolution (DirectEvolution(TM)). These methods include non-stochastic polynucleotide site-satuaration mutagenesis (Gene Site Saturation Mutagenesis(TM)) and non-stochastic polynucleotide reassembly (GeneReassembly(TM)). Through use of the claimed methods, vectors can be obtained which exhibit increased efficacy for use as genetic vaccines. Vectors obtained by using the methods can have, for example, enhanced antigen expression, increased uptake into a cell, increased stability in a cell, ability to tailor an immune response, and the like.

This invention provides methods of obtaining novel polynucleotides and encoded polypeptides by use of non-stochastic methods of directed evolution (DirectEvolution(TM)). These methods include non-stochastic polynucleotide site-saturation mutagenesis (Gene Site Saturation Mutagenesis(TM)) and non-stochastic polynucleotide reassembly (GeneReassembly(TM)). Through use of the claimed methods, genetic vaccines, enzymes, and other desirable molecules can be evolved towards desirable properties. For example, vaccine vectors can be obtained that exhibit increased efficacy for use as genetic vaccines. Vectors obtained by using the methods can have, for example, enhanced antigen expression, increased uptake into a cell, increased stability in a cell, ability to tailor an immune response, and the like. This invention provides methods of obtaining novel enzymes that have optimized physical &/or biological properties. Furthermore, this invention provides methods of obtaining a variety of novel biologically active molecules, in the fields of antibiotics, pharmacotherapeutics, and transgenic traits.

The present invention is differentiated adipose tissue-derived stromal cells that exhibit the improved properties of increased extracellular matrix proteins and/or a lower amount of lipid than a mature isolated adipocyte. Methods for the expansion and differentiation of these cells are also provided. The cells of the invention are used for the treatment, repair, correction and/or regeneration of soft tissue cosmetic defects.

The present invention is preparation process of collagen-based surface wound repairing membrane possessing tissue induction function, and features that the collagen-based surface wound repairing membrane modified physically and chemically has introduced gelatin-base slow releasing microsphere containing cell growth factor, pores of 20-200 micron size, pore rate not smaller than 80 %, tensile strength not smaller than 1 MPa, pH 5.0-6.0, and excellent degradation and biocompatibility. It has the functions of absorbing wound diffusate, induce the adhesion, proliferation and differentiation of autocell, induce the growth of blood vessel, release cell growth factor to the wound for long time, speed wound healing and avoid scar. The present invention is used for injury, burns, scalds, skin ulcer, etc.

The invention discloses a total bufogenin extract with antitumor function and also discloses a preparation method of the extract and application thereof in the preparation of antitumor medicines. The total bufogenin extract of the invention is prepared by organic solvent extraction, column chromatography separation and purification of dried toadskin; the content of total bufogenin is over 80 percent, wherein the content of resibufogenin is over 12 percent, the content of cinobufagin is over 4 percent, and the content of bufotalin is over 10 percent. Compared with the prior art, the invention eliminates bufotenine alkaloid which has irritation, is easy to cause hypersensitivity but has no antitumor activity, efficiently collects the effective part of total bufogenin which has significant antitumor activity, therefore pharmacological action is stronger, the clinical curative effect is higher and the toxic and side effect is lower. The total bufogenin extract can be prepared into various pharmaceutical preparations for clinical application, therefore the invention has the functions of killing tumor cells, inducing differentiation and apoptosis of tumor cells, inhibiting the neovascularization of tumor cells and lowering the neoplasm metastasis rate, etc.

The present invention relates to a composition for promoting differentiation of pluripotent stem cells into cardiac muscle cells, and a method for inducing differentiation of pluripotent stem cells into cardiac muscle cells and a method for preparing cardiac muscle cells

The present invention provides compositions and methods for activation and expansion of T cells using a biocompatible solid substrate with tunable rigidity. Rigidity of a substrate is an important parameter that can be used to control the overall expansion and differentiation of T cells.

The present invention is directed to compounds of the general formula (I)

or pharmaceutical acceptable salts or physiologically functional derivatives thereof wherein: n is a non-aromatic ring system containing two to seven carbon atoms, wherein the ring system can contain one ore two double bonds;

• • X is C, CH or CH₂;
  • Y is selected from C, CH, CH₂, S, NR, CH₂-CH₂,
  • H₂C—CH, HC—CH₂, C—CH₂, H₂C—C, or C—C; one or more of the hydrogen atoms can optionally be substituted by one or more substituents R′; each of the dotted lines means a single, a double or triple bond with the exclusion of a combination of a triple with triple bond and a double with a triple bond; R′ is independently H, —CN, alkyl, cycloalkyl, aminoalkyl, alkylamino, alkoxy, —OH, —SH, alkylthio, hydroxyalkyl, hydroxyalkylamino, halogene, haloalkyl, haloalkyloxy; R is H, an alkyl or cycloalkyl group; Z is CH, C, or P; p is 0 or 1.

The invention relates to the technical field of plant growth regulators. The plant growth promoter is mainly designed for solving the technical problems that existing plant growth promoters have a poor plant absorption effect, and destroy the soil environment. The plant growth promoter is prepared from natural extracts, a growth stimulator, cytokinin, a cell activator, amino acid and water. The plant growth promoter disclosed by the invention has a good promotion effect on the growth of plants, has a high plant utilization rate, takes an effect quickly, and has no pollution to the environment.

The invention discloses an inulin soya-bean milk beverage and a preparation method thereof, belonging to the technical field of food processing. The inulin soya-bean milk beverage disclosed by the invention mainly consists of the following components in parts by weight: 80-120 parts of soya-bean milk, 2-20 parts of inulin, 1-5 parts of honey and 0.1-0.4 parts of a stabilizer, wherein the inulin, which is also called as synanthrin, is linear straight-chain polysaccharide formed by D-fructose through key jointing of beta (1 to 2), the tail end of the inulin is provided with a glucose residue, and the degree of polymerization is 2-60. The inulin, as a soluble dietary fiber different from a starch structure, can selectively promote the growth of colon probiotics and improve the health condition of a host. The inulin soya-bean milk beverage disclosed by the invention is white, is exquisite and smooth in mouth feel, has a low caloric value and can promote the growth of human colon probiotics, inhibit toxic fermentation products, promote the absorption of mineral materials such as calcium, magnesium and iron and improve the physiological functions such as immunity of the organism.

The invention relates to the cancer antigen PRAME (PReferentially expressed Antigen in MElanoma) and its use in a method of treatment of a tumour which comprises administering to a subject in need of treatment an effective amount of an inhibitor of PRAME, in combination with a second agent selected from the group of an inhibitor of HDAC (an HDACi) and a retinoid.

The invention discloses a preparation method and an application of an ecdysone-rich plant standardized extract. The preparation method comprises the steps of: extracting ecdysone-rich plant materials using ethanol under reflux, filtering, concentrating and centrifuing; decolorizing the centrifuged supernatant, purifying by macroporous resin column chromatography, concentrating and drying to obtain the standardized extract. The method is simple and feasible, short in production period, and stable and controllable in quality, and is easy for preparation and industrial production in a standardized and batch manner; and the similarity of the extract obtained by the method is more than 99% by HPLC (high performance liquid chromatography) fingerprint spectrum detection. The extract can be applied in preparing fixed preparations serving as drugs for reducing blood sugar and resisting rheumatoid arthritis, can be used as a raw material for natural cosmetics and can be applied in animal breeding industry.

The invention discloses a three-dimensional bionic self-healing hydrogel fiber scaffold composition and a preparation method and application thereof. The scaffold composition is composed of a biocompatible material, a nano material and a small molecular compound. By using electrostatic spinning, self-crosslinking and mold forming methods, a mixed solution of the biocompatible material, the nano material and the small molecular compound is mixed with an organic solvent in proportion to form a scaffold with biomedical application, particularly a layer-by-layer self-crosslinking three-dimensionalscaffold for muscle regeneration. The biomedical hydrogel fiber scaffold disclosed by the invention can provide cell adhesion sites and signals for inducing cell proliferation and differentiation, has excellent mechanical strength and biodegradability, and has the characteristics of easiness in preparation, low cost, good compatibility and wide application. Rat in-vivo experiments show that: thethree-dimensional bionic hydrogel fiber scaffold can induce differentiation of muscle fibers, reduce oxidative damage to cells and tissues and promote regeneration of muscles and new vessels, and hasgood clinical application conversion value.

New uses of proteoglycans to bind and present growth factors, methods of accelerating wound, tissue or bone repair using such proteoglycans, pharmaceutical compositions of such proteoglycans, and scaffolds coated with such proteoglycans are disclosed. The proteoglycan of the invention is derived from domain I or perlecan.

The invention belongs to a filed of medicine technology, which relates to a novel pair of panaxsapogenol and a medical application of a mixture thereof. The pair of compounds are 20(R)-25-methoxyl-dammarane-3beta, 12beta, 20-triol(25Rmdt for short) and 20(S)-25-me-thoxyl-dammarane-3beta, 12beta, 20-triol(25Smdt for short). The 25Rmdt and 25Smdt and the mixture thereof have the antitumor activities of inhibiting the growth and multiplication of a plurality of tumor cells, inducing the differentiation and withering of tumor cells, inhibiting the generation of tumor angiogenic blood vessels, inhibiting the invasion and transfer of tumors, enhancing the body immunity and reducing the toxic and side effects of chemotherapeutic drugs, which is substantially used for treating malignant tumors, with a total effective dosage of 1-100mg/kg/d.

The present invention relates to a method for predicting the response of a patient to treatment with an anti-TNFα therapy, in particular an anti-TNFα antibody, the method comprising: (a) providing an in vitro sample of T cells from the patient; (b) exposing said T cells to an anti-TNFα therapy; and (c) determining whether regulatory T cells are induced in said sample of T cells wherein the induction of regulatory T cells indicates that the patient is likely to respond to treatment with said anti-TNFα therapy.

The invention provides an application of a method for the autocrine secretion of an extracellular matrix by stem cells and the induction of the stem cells to become hepatocytes. The extracellular matrix is secreted by inducing bone marrow mesenchymal stem cells and removes the matrix of the bone marrow mesenchymal stem cells. The invention concretely provides the method for inducing the bone marrow mesenchymal stem cells into hepatocytes by the extracellular matrix according to actual demands. The method for generating the hepatocytes through induction has the advantages of high efficiency, practicality, high induction efficiency and good differentiation effect, and the glycogen synthesis capability and the urea synthesis capability of the hepatocytes obtained after the induction are strong.

The present invention relates to compositions and methods for inducing mammary epithelial cell differentiation in mammalian subjects. More specifically, the present invention relates to methods for inducing mammary epithelial cell differentiation which comprise increasing the levels of galanin in the mammary tissue of the subject. In one aspect the present invention relates to a method of increasing milk production in a lactating mammal which comprises increasing the level of galanin or an analog thereof in the mammal. In another aspect the present invention relates to a method of enhancing mammary development in a mammal, the method comprising administering to the mammal galanin or an analog thereof in conjunction with prolactin or an analog thereof. In yet another aspect the present invention relates to a method for inhibiting mammary epithelial tumours by administering an inhibitorially effective therapeutic amount of galanin or an analog thereof.

Described are compounds and methods useful for selectively targeting cancer stem cells. The compounds preferentially induce differentiation and/or reduce the proliferation of cancer stem cells relative to normal stem cells. Compounds useful for selectively targeting cancer stem cells include polyene macrolides such as Nystatin or Amphotericin B, analogs thereof and pharmaceutically acceptable salts thereof.

An adiponectin enhancer comprising as an active ingredient sesamin and/or episesamin, or an analogue thereof.

A method of inducing or promoting hair growth on the scalp of a subject, comprising the steps of (i) providing an ECM composition including at least one ECM material, (ii) administering inciting event means to a target location on the scalp of the subject to induce an inciting event at the target scalp location, and (iii) administering a therapeutically effective amount of said ECM composition to the target scalp location. In some embodiments, the ECM composition includes at least one additional biologically active agent.